HC Wainwright Begins Coverage on Odyssey Therapeutics (NASDAQ:ODTX)

HC Wainwright began coverage on shares of Odyssey Therapeutics (NASDAQ:ODTX) in a note issued to investors on Friday, Marketbeat reports. The firm set a “buy” rating and a $40.00 price target on the stock. HC Wainwright‘s target price points to a potential upside of 108.01% from the stock’s previous close. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q1 2027 earnings at ($1.27) EPS, Q2 2027 earnings at ($1.29) EPS, Q3 2027 earnings at ($1.29) EPS and Q4 2027 earnings at ($1.28) EPS.

A number of other research analysts have also weighed in on ODTX. Weiss Ratings started coverage on shares of Odyssey Therapeutics in a research note on Tuesday, August 11th. They issued a “sell (d+)” rating on the stock. UBS Group started coverage on Odyssey Therapeutics in a report on Monday, October 12th. They issued a “buy” rating and a $27.00 price objective for the company. JPMorgan Chase & Co. increased their target price on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, Raymond James Financial started coverage on Odyssey Therapeutics in a research report on Thursday, October 8th. They set an “outperform” rating and a $42.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.67.

Odyssey Therapeutics Price Performance

NASDAQ:ODTX opened at $19.23 on Friday. Odyssey Therapeutics has a 52 week low of $15.10 and a 52 week high of $29.05. The company’s 50-day simple moving average is $21.18. The firm has a market cap of $924.39 million and a PE ratio of -2.84.

Odyssey Therapeutics (NASDAQ:ODTX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. As a group, equities research analysts expect that Odyssey Therapeutics will post -6.18 earnings per share for the current year.

Institutional Trading of Odyssey Therapeutics

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. bought a new position in Odyssey Therapeutics in the third quarter worth about $28,000. The Manufacturers Life Insurance Company acquired a new position in Odyssey Therapeutics in the second quarter valued at approximately $601,000. State Street Corp purchased a new stake in shares of Odyssey Therapeutics during the 2nd quarter worth about $1,477,000. Aberdeen Group plc grew its stake in Odyssey Therapeutics by 4.7% in the 3rd quarter. Aberdeen Group plc now owns 172,771 shares of the company’s stock valued at $3,839,000 after acquiring an additional 7,771 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in Odyssey Therapeutics in the 2nd quarter worth about $4,162,000.

Odyssey Therapeutics Company Profile

Odyssey Therapeutics is a clinical-stage biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, functional genomics, and experimental drug discovery to identify therapies directed at disease-driving biological pathways.

Its research programs are centered primarily on small-molecule medicines and other targeted approaches intended to modulate the immune system or address vulnerabilities in cancer cells.